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Soluble Triggering Receptor 
Expressed on Myeloid Cells 1 in lung 
cancer
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Rainer Wiewrodt2, Arik Bernard Schulze2, Roland Buhl1 & Markus Radsak1
Soluble Triggering Receptor Expressed on Myeloid Cells 1 (sTREM-1) can be found in the sera of patients 
with infectious, autoimmune and malignant diseases. The primary objective of this study was to 
investigate the prognostic significance of sTREM-1 in lung cancer patients. We analyzed the sera of 
164 patients with lung cancer of all histologies and all stages at the time of diagnosis. We employed 
an ELISA using the anti-TREM-1 clone 6B1.1G12 mAb and recombinant human TREM-1. Patient data 
was collected retrospectively by chart review. In ROC-analysis, a sTREM-1 serum level of 163.1 pg/
ml showed the highest Youden-Index. At this cut-off value sTREM-1 was a marker of short survival in 
patients with NSCLC (median survival 8.5 vs. 13.3 months, p = 0.04). A Cox regression model showed 
stage (p < 0.001) and sTREM-1 (p = 0.011) to indicate short survival. There were no differences in 
sTREM-1 serum values among patients with or without infection, pleural effusion or COPD. sTREM-1 
was not associated with metastasis at the time of diagnosis and was not a predictor of subsequent 
metastasis. In SCLC patients sTREM-1 levels were lower than in NSCLC patients (p = 0.001) and did not 
predict survival. sTREM-1 did not correlate with CRP or the number of neutrophils. In non-small cell lung 
cancer patients, sTREM-1 in serum has prognostic significance.
Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1, CD354) is an innate inflammatory transmembrane 
receptor first described to be expressed by neutrophils and monocytes1. Later, expression has also been reported 
on various non-immune cells like endothelial cells2 and bronchial epithelium3. TREM-1 is believed to amplify 
both infectious and non-infectious inflammation4 and to elicit the release of TNF-alpha, IL-8, myeloperoxidase 
and nitric oxide by innate immune cells1. The TREM-1 ligand has not been unequivocally identified so far, but 
several reports suggest HSP705, HMGB16 and PGLYRP17. On platelets, extracellular actin has recently been sug-
gested as a novel TREM-1 ligand8. Moderate expression of TREM-1 during sepsis seems to improve survival in 
mice, but high expression increases mortality9.
During sepsis TREM-1 expression is enhanced and released in a soluble form (sTREM-1). sTREM-1 is a 
27 kDa polypeptide consisting of the extracellular domain of TREM-1, that is shed from the cell surface by metal-
loproteinases (MMP)10. In addition, sTREM-1 may be produced as an alternative splicing variant of the TREM-1 
mRNA11. Initially, sTREM-1 has been proposed to be an accurate marker for infectious diseases such as pneumo-
nia12 and sepsis13, but later on sTREM-1 in sera has also been found in many non-infectious diseases like COPD14, 
pancreatitis15 and inflammatory bowel disease16. Hence sTREM-1 can be regarded as a marker for severity of 
innate inflammation17,18. sTREM-1 may act as a kind of decoy receptor for TREM-1 ligands in blood and thus as 
an anti-inflammatory mediator19,20.
In lung cancer, TREM-1 is not expressed by cancer cells, but cancer cells induce the expression of TREM-1 
in macrophages21,22. These tumor associated macrophages (TAM) may induce a micro-environment promoting 
tumor growth and nidation of metastatic tumor cells23,24. Thus, TREM-1 expression in TAMs is an independent 
predictor of poor survival in NSCLC21.
Corresponding to the supposed anti-inflammatory role of sTREM-1 in inflammation, a study in solid malig-
nancies including lung cancer found sTREM-1 in patients’ sera to be correlated with the absence of metastasis25. 
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Contradictory to this, a doctoral thesis found sTREM-1 in sera to be correlated with short survival in lung cancer 
patients with pleural effusion26.
Therefore we conducted the current study to clarify whether sTREM-1 in sera of patients with lung cancer 
either indicates better survival perhaps by acting anti-inflammatory and preventing metastasis or is an indicator 
of a fatal inflammatory state leading to shorter survival. Several secondary questions were also addressed: Which 
cut-off would be used best to discriminate between patients with short and long term survival? Do other diseases 
known to induce sTREM-1 in sera influence the level of sTREM-1 in lung cancer patients? Does the level of 
sTREM-1 in sera indicate the presence of pleural effusion or solid metastasis? Can sTREM-1 be used to predict 
the subsequent occurrence of metastasis in patients treated with curative intention? And finally, is it possible to 
predict success of anti-cancer therapies by sTREM-1 measurement?
Results
sTREM-1 cut-off values. The median level of sTREM-1 in sera was 179.6 pg/ml (minimum 7.7 pg/ml, 
maximum 1048.3 pg/ml) and the 90th percentile was 361.5 pg/ml. Regarding NSCLC patients only, median level 
of sTREM-1 was 191.9 pg/ml and 90th percentile was 403.1 pg/ml. In SCLC patients, median level of sTREM-1 
was 127.9 pg/ml and 90th percentile was 261.1 pg/ml. None of these cut-off values was predictive for survival in 
Kaplan-Meier analysis and Cox Regression analysis (data not shown).
We performed a ROC-analysis to determine the level of sTREM-1 predicting survival shorter than the median 
with the highest Youden’s Index (sensitivity + specificity − 1). Median survival was 10.6 months and only 8.5% 
of all cases were censored in the study population. The analysis found 3 different levels of sTREM-1 to have an 
equal Youdens’s Index of 0.195. Of those values, we chose 163.1 pg/ml (42th percentile) as cut-off, because this 
value displayed the highest specificity and all further survival analysis was done using this cut-off. Sensitivity for 
detecting a survival shorter than the median was 0.51 and specificity was 0.68 (Fig. 1A).
Figure 1. (A) ROC-Analysis of sTREM-1 for predicting short survival (the crossing lines mark the highest 
Youden index at 163.1 pg/ml) (B) Kaplan Meier Analysis all patients (n = 164) (C) Kaplan Meier Analysis in 
NSCLC patients (n = 137) (D) Kaplan Meier Analysis in stage IV NSCLC patients (n = 75).
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Prognostic value in all patients. Patient characteristics of the study population and subpopulations are 
summarized in Table 1. In the overall study population (n = 164) Kaplan-Meier analysis did not show a prog-
nostic value of sTREM-1 (log rank test p = 0.084, Fig. 1B), but a trend towards shorter survival for patients with 
sTREM-1 levels higher than 163.1 pg/ml. We performed a multivariate Cox Regression analysis in these patients. 
The factors age, sex, histology, and sTREM-1 were included in this model. As stage grouping for NSCLC and 
SCLC were incomparable, we included the presence of metastasis as an additional possible prognostic factor. We 
found metastasis and sTREM-1 to be of prognostic value (metastasis: p < 0.0001, sTREM-1: p = 0.02) but not sex, 
age and histology (Table 2).
Prognostic value in NSCLC patients. In subpopulation A (all NSCLC patients, n = 137) Kaplan-Meier 
analysis showed, that patients with a sTREM-1 serum level higher than the cut-off had shorter survival (median 
survival 8.5 vs. 13.3 months, p = 0.04, Fig. 1C). We performed a multivariate Cox Regression analysis in these 
patients. The factors age, sex, histology, stage and sTREM-1 were included in this model. We found stage and 
sTREM-1 to be of prognostic value (stage: p < 0.0001, sTREM-1: p = 0.011) but not sex, age and histology 
(Table 2).
Regarding stage IV patients (subpopulation D, n = 75), Kaplan-Meier analysis showed, that a high sTREM-1 
level was a strong predictor of shorter survival (median survival 4.8 vs. 11.4 months, p = 0.009; Fig. 1D). This 
was confirmed by a Cox regression model that found a hazard ratio of 1.9 for patients with high sTREM-1level 
in serum (Table 2).
Prognostic value in SCLC patients. In subpopulation B (SCLC patients, n = 27), we found a trend towards 
shorter survival in patients with a sTREM-1 serum level higher than the cut-off (p = 0.07). In the multivariate 
analysis none of the factors (age, sex, stage and sTREM-1) was accepted.
Prediction of stage or metastasis in NSCLC patients. In a Kruskal-Wallis test, sTREM-1 levels were 
not different in patients with distinct stages of NSCLC (subpopulation A, p = 0.929; Fig. 2A). There was no asso-
ciation of sTREM-1 with the site of metastasis, especially not with lung metastasis (p = 0.444) at the time of 
primary diagnosis. In patients with NSCLC stage I-IIIb (subpopulation C), the Kruskal-Wallis test did not show a 
difference in sTREM-1 values of patients who had a new metastasis after therapy and those who experienced local 
recurrence during the course of the disease.
Association of sTREM-1 with histology. There was a significant difference in sTREM-1 between NSCLC 
and SCLC patients, but not between subtypes of NSCLC (Fig. 2B,C). sTREM-1 serum levels were higher in 
NSCLC patients (Mann-Whitney U-test p = 0.001). Of the 62 patients with adenocarcinoma, 29 patients had 
an evaluation of the adenocarcinoma subtype. We found a trend towards higher sTREM-1 levels in patients 
with acinar adenocarcinoma and bronchioalveolar carcinoma, but the trends did not reach significance in the 
Study 
population
Subpopulation
A B C D E
n 164 137 27 62 75 103
Sex (male) 118 (72%) 100 (73%) 18 (67%) 44 (71%) 56 (75%) 76 (74%)
Age (years) 63 63 66 63 62 65
NSCLC 137 (84%) (100%) 0 (100%) (100%) 90 (88%)
NSCLC subtype
ACa 62 (38%) 62 (45%) 27 (44%) 35 (47%) 45 (44%)
SCCb 56 (34%) 56 (40%) 27 (44%) 29 (39%) 33 (32%)
AC/SCCc 4 (2%) 4 (3%) 4 (7%) 0 2 (2%)
LCCd 4 (2%) 4 (3%) 0 4 (5%) 4 (4%)
Neuroe 2 (1%) 2 (2%) 1 (2%) 1 (1%) 2 (2%)
Carcinoid 2 (1%–9) 2 (2%) 2 (3%) 0 2 (2%)
Carc.-sarc.f 2 (1%) 2 (2%) 0 2 (3%) 0
NOSg 5 (3%) 6 (4%) 1 (2%) 4 (5%) 2 (2%)
NSCLC stage
I 14 (9%) 14 (10%) 14(23%) 13 (12%)
II 8 (5%) 8 (6%) 8(13%) 6 (6%)
III 40(24%) 40(29%) 40(65%) 24 (23%)
IV 76 (46%) 75 (55%) (100%) 47 (46%)
SCLC 27 (17%) 0 (100%) 0 0 13 (12%)
SCLC stage
LD 5 (3%) 5 (18%) 3 (3%)
ED 22 (14%) 22 (82%) 10 (10%)
COPD n.a. n.a. n.a. n.a. n.a. 43 (41%)
Pneumonia or sepsis n.a. n.a. n.a. n.a. n.a. 13 (13%)
Table 1. Patient characteristics of the study population and subpopulations. aadenocarcinoma, bsquamous 
cell carcinoma, cadenosquamous carcinoma, dlarge cell carcinoma, eneuroendocrine differentiated carcinoma, 
fcarcinosarcoma, gNSCLC not otherwise specified.
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Mann-Whitney U-test. Of note, when analyzing sTREM-1 values in percentiles, we did not find a patient with 
SCLC and a sTREM-1 serum level above the 90th percentile (chi square-test p = 0.041), thus very high levels of 
sTREM-1 could indicate NSCLC.
Association of sTREM-1 with co-morbidity. In subpopulation E we analyzed, whether there was an 
association between sTREM-1 values in sera and the presence of co-morbidities like infection (pneumonia or 
sepsis) or COPD. A Kruskal-Wallis test demonstrated a trend towards higher levels of sTREM-1 in infectious 
diseases, but the test did not reach significance (p = 0.084; Fig. 2D). In Kaplan-Meier analysis infection was not a 
predictor of survival (p = 0.520). CRP was reported in 75 patients at the time of blood sampling for sTREM-1. In 
a linear regression model, sTREM-1 was independent of CRP (R square = 0.088). CRP was associated with infec-
tion in Kruskal-Wallis test, but not with survival in a Cox Regression model. There was no correlation of sTREM-1 
with LDH (n = 57; R square = 0.05), NSE (n = 108; R square = 0.013), Cyfra (n = 107; R square = 0.015), or CEA 
(n = 111; R square = 0.005). The total leucocyte count, the percentage of neutrophils and the absolute number of 
neutrophils (n = 28) did not correlate with sTREM-1 values (R square = 0.05, 0.044 and 0.218).
Association of sTREM-1 with treatment and response to chemotherapy. Cancer treatment had 
an impact on sTREM-1 serum levels. 114 Patients (70%) had therapy after sampling for sTREM-1. In 5% of all 
cases, no treatment data were available. If treatment started prior to the blood sampling, the therapy consisted 
of chemotherapy in most patients (92%). Regarding NSCLC and SCLC patients, sTREM-1 levels were higher, 
when the blood sample was taken prior to therapy (Mann-Whitney-U-test p < 0.001), but did not correlate with 
survival. In the 95 NSCLC patients with a blood test prior to therapy, high sTREM-1 values predicted shorter sur-
vival (Kaplan-Meier analysis log rank p = 0.042). We could not confirm these results by multivariate analysis. In 
NSCLC patients, who had the blood sample after therapy started, we could not observe any difference in survival, 
but the sample size was low (n = 34). 46 patients had a blood sample before receiving chemotherapy alone for 
SCLC or NSCLC and had a response evaluation. A Kruskal-Wallis test showed no association of sTREM-1 with 
the response to chemotherapy (p = 0.724).
study population (n = 164) HRb
FWDa
95% CIc pd
Agee 0.235
Sexf 0.987
Histologyg 0.099
Metastasish 3.9 × 10−11
sTREM-1i 1.48 1.06–2.06 0.020
Subpopulation A (n = 137) HRb FWD
a
95% CIc p
d
Agee 0.058
Sexf 0.816
sTREM-1i 1.6 1.08–2.39 0.011
Stage 4.9 × 10−11
  1 vs. 2 1.8 0.61–5.17
  2 vs. 3 3.0 1.38–6.64
  3 vs. 4 8.3 3.81–18.01
Histology
  ACj 0.163
  SCCk 0.388
  LCCl 0.081
Subpopulation D (n = 75) HRb FWD
a
95% CIc p
d
Agee 0.518
Sexf 0.175
sTREM-1i 1.94 1.17–3.2 0.008
Histology
  ACj 0.193
  SCCk 0.706
  LCCl 0.137
Table 2. Cox regression models for overall survival in all patients, in all NSCLC patients and in stage 
IV NSCLC patients, aForward likelihood ratio model, bHazard ratio: HR < 1 suggests improved survival, 
cConfidence interval, dP-value according to the likelihood ratio test, ePer anno, fFemale vs. male, gNSCLC vs. 
SCLC, hM0 vs M1, iSTREM-1 lower vs. higher than 163.1 pg/ml, jO ther NSCLC vs. adenocarcinoma, kOther 
NSCLC vs. squamous cell carcinoma, lOther NSCLC vs. large cell carcinoma.
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Discussion
The present study demonstrates high sTREM-1 levels in sera as a predictive marker of short survival in NSCLC 
patients and to be unrelated to the concurrent presence of COPD and infection. NSCLC patients show higher 
sTREM-1 serum levels than SCLC patients, but we were unable to demonstrate a correlation of sTREM-1 with 
distinct subtypes of NSCLC, CRP or tumor markers, and there was no association with stage, metastasis or 
response to chemotherapy.
However, sTREM-1 release might depend on other conditions than infection, non-infectious inflammation 
or cancer. A recent study27 suggests, that the Trem1 genotype (i.e. the presence of the single nucleotide polymor-
phism rs2234246) might contribute to higher or lower sTREM1 levels, irrespective of the factors investigated in 
our study. Moreover, in our patient series, we do not have complete data on the presence of COPD and infection 
in every patient as the chart review was done retrospectively. Another limitation of our study is the lack of testing 
for activating EGFR-mutations although it has an important effect on patients’ survival28, due to the fact that this 
was not part of the clinical routine in 2000–2005, when our patients were diagnosed with lung cancer.
The strength of our study is the possibility of studying patients who homogeneously had blood testing 
for sTREM-1 at the time of first histological diagnosis. Yet, in 25% of our patients therapy was started before 
sTREM-1 serum testing. These patients had lower levels of sTREM-1 and the impact of sTREM-1 on survival was 
less evident in this group of patients.
When comparing our results to other studies, it has to be considered, that there are several ELISAs for the 
detection of sTREM-1 available, which might differ significantly as indicated by the range of cut-off values used 
in different studies29. The ELISA used the study of Hasibeder et al.29 is most related to our test. We requested data 
on sTREM-1 levels in healthy volunteers (n = 4) from the authors (personal communication). The median serum 
level of sTREM-1 in this population was 66.1 pg/ml, which is markedly lower than in our patient population 
Figure 2. (A) Boxplot sTREM-1 in NSCLC stage I vs. II vs. III vs. IV (B) Boxplot sTREM-1 in different 
subtypes of NSCLC (C) Boxplot sTREM-1 and Histology (D) Boxplot sTREM-1 in lung cancer patients vs. 
patients with lung cancer and COPD vs. patients with lung cancer and infection vs. patients with lung cancer 
and infection and COPD).
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(median level 179.6 pg/ml). Because the numbers were too low for a reliable statistical analysis, we did not per-
form a Mann-Whitney-U-test or a ROC-analysis.
In a doctoral thesis, Enste analyzed 107 patients with pleural effusion by a comparable ELISA procedure as 
described in our study26. 47 of the patients had lung cancer, 49 had cancer of another primary site and 11 had no 
malignant disease. Of note, lung cancer patients did not have higher sTREM-1 values in sera than patients without 
malignancy in that study. The author demonstrated that in the subpopulation of 40 NSCLC patients with pleural 
effusion (stage III and IV according to UICC 6th TNM Edition) sTREM-1 levels higher than the median of 50 pg/
ml correlated with shorter survival. In contrast to our study, the blood sample was taken at an individual time point 
during that disease, but the results correspond to our finding of sTREM-1 being a negative prognostic marker.
Karapanagiotou et al. investigated sTREM-1 in a population of 59 cancer patients including 15 patients with 
NSCLC and 15 patients with SCLC25. In that study, a cut-off value of 15 pg/ml was used. 13% of NSCLC and 33% 
of SCLC patients exceeded the cut-off which contrasts our finding of higher sTREM-1 serum levels in NSCLC 
patients.
In the pooled analysis of all cancer patients, Karapanagiotou et al. found that high sTREM-1 levels indicated 
the absence of lung metastasis but not the absence of other metastasis. Obviously, absence of metastasis indicates 
longer survival in lung cancer. In our study, we could not demonstrate an association with the site of metasta-
sis despite a larger study population. Maybe the effect reported by Karapanagiotou et al. is mainly determined 
by the patients with non-lung cancer entities (breast cancer and colorectal cancer) in their study population. 
Furthermore the authors use a similar ELISA detection kit as we did in our study, but we lack information if the 
same capture antibody was used29.
In our study, we present the largest analysis of sTREM-1 in sera of lung cancer patients so far. By analyzing 
the co-morbidities, we can broadly rule out that our main finding of sTREM-1 indicating short survival is con-
founded by serious infection, a condition that sTREM-1 can also indicate12. Our results are in line with the study 
of Enste26 and complement a study of Ho et al., who investigated TREM-1 expression in lung cancer tissue by 
immunohistochemistry21.
A possible explanation why patients with high sTREM-1 in serum have a worse prognosis might be that more 
sTREM-1 is shed from the immune cells surrounding the tumor because of enhanced MMP-activity. MMPs play 
a role in the degradation of the extracellular matrix during cancer progression and tissue invasion30, thus high 
MMP-activity might indicate a highly aggressive tumor. As we were unable to show an association with tumor 
stage, this correlation seems insufficient to completely explain the underlying biology. Moreover, we found higher 
sTREM-1 levels in NSCLC than in SCLC, an entity which is considered to be more aggressive than NSCLC. There 
are few comparisons of MMPs in SCLC and NSCLC in literature, but MMP-2 seems to be more often expressed on 
NSCLC cells than on SCLC cells31,32. Regarding MMP-9, higher activity in tumor tissues is reported in NSCLC than 
in SCLC33. Potentially, some MMPs might be more relevant for shedding sTREM-1 than others and distinct activity 
of these MMPs explains our finding of lower sTREM-1 in SCLC. However, this needs to be clarified in future studies.
From the study of Ho et al., it is already known that TREM-1 is not expressed on lung cancer cells, but on 
tumor associated macrophages and that the expression on TAMs could be used to predict short survival in a pop-
ulation of 68 NSCLC patients21. Considering that sTREM-1 is the extracellular domain of TREM-1 shed from the 
cell surface10, it would be plausible that high expression of TREM-1 in TAMs lead to high sTREM-1 concentration 
in serum. In that case, high TREM-1 expression in TAMs and high levels of sTREM-1 in sera could both indicate, 
that a tumor micro environment has been established that probably promotes tumor growth and therefore signi-
fies an unfavorable course of the disease24. In some way contradictory to the study of Ho et al.21, there is a smaller 
study which demonstrated less TREM-1 expression in TAMs than in macrophages from normal lung tissue by 
flow cytometric assays34.
Apart from monocytes/macrophages, neutrophils are a major source of sTREM-1. Neutrophils have faster 
kinetics when shedding sTREM-1 from the cell surface10. A study in asthma reported that sTREM-1 levels corre-
late with neutrophil counts18. We did not observe high sTREM-1 levels in patients with high neutrophil numbers 
in our study.
Recently, checkpoint-inhibitor therapy has fundamentally changed lung cancer treatment. PD-1 is expressed 
on TAMs35 which are believed to play a major role in the interaction of tumor cells with their micro environment, 
which results in immune evasion36. Recent reports suggest that the effect of checkpoint-inhibitor therapy is at 
least partly mediated by TAMs37. In many entities and especially in lung cancer, TAMs seem to polarize to a so 
called M2 state, which is characterized by CD204 and CD163 expression and promotes tumorigenesis, angiogen-
esis, remodeling of the extracellular matrix and suppression of immune response38,39. In flow cytometric assays, 
almost all PD-1-positive TAMs express an M2-like surface profile37.
In non-malignant disease, hypoxia induced TREM-1-expression on macrophages normally induces a shift 
from the M2 to the M1 state, which should lead to antimicrobial defense an antitumor resistance40,41.
Currently in lung cancer, there are no published studies which investigated how TREM-1 positive TAMs are 
polarized. A correlation of TREM-1 and the M2 state could explain why the beneficial purpose of TREM-1 in 
infectious disease gained an opposite role in cancer.
Certainly, our study has the limitation that we are unable to correlate our results with immunohistochemistry 
using a TREM-1 antibody on the patients‘ tumor specimens as we lack the respective tumor samples. This issue 
should be addressed in a prospective trial in which blood and tumor samples are available. However, one has 
to consider that the available sTREM-1 ELISAs differ significantly in precision and accuracy29 and need to be 
improved before thinking of applying sTREM-1 testing in clinical routine.
In conclusion, sTREM-1 may be an interesting surrogate biomarker for TAM activity in NSCLC patients 
fostering prospective studies investigating whether TREM-1 and PD-1 expression in TAMs both represent the 
tumor associated M2 state and secondarily whether sTREM-1 can be used as a peripheral blood surrogate marker 
for this state and potentially as a predictor of checkpoint-inhibitor effectiveness.
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Materials and Methods
We analyzed 164 serum specimens of patients who were referred to our tertiary care center (Pulmonary Division 
of Gutenberg-University Medical Center, Mainz, Germany) with highly suspected lung cancer or with newly 
diagnosed lung cancer between 2000 and 2005. Identification of patients, data acquisition and statistical methods 
were adopted from one of our previous studies in lung cancer42. Blood samples were taken within 30 days prior 
to or after the histopathological diagnosis of lung cancer. The analysis was done in excess material which would 
otherwise have been disposed after routine diagnostics. The patients gave written consent and the state ethics 
committee approved this procedure. The samples were immediately centrifuged; sera were aliquoted and frozen 
at −80 °C. We reviewed the medical records for age, gender, smoking history, co-morbidities, histology, tumor 
markers (i.e. carcinoembryonic antigen (CEA), cytokeratin fragment 19 (Cyfra), LDH, and neuron-specific eno-
lase (NSE)), clinical staging (according to IUCC/AJCC recommendations including clinical examination, CT 
scans, bone scan, optional sonography and endoscopy, MRI of the brain if metastasis was suspected or had to be 
excluded), pathological staging if patients had surgery and therapy data. TNM-staging was based on UICC 6th 
TNM Edition43 and histologic classification was based on the 1999/2004 WHO consensus44,45. The study popu-
lation included patients with non-small cell lung cancer (NSCLC) of stages IA to IV (Classification according to 
Mountain46) and small cell lung cancer (SCLC) patients with limited (LD) or extensive (ED) disease (Veterans’ 
association47). Of note, because patients were staged using UICC 6th TNM Edition, 5 of the 22 patients with 
pleural effusion but without metastasis were set to have stage III disease. Adenocarcinoma subtypes were only 
described in 29 of 62 cases based on the WHO classification of tumors published in 199945. Regarding first line 
therapy, 20 patients (12%) underwent anatomic resection with lymph node dissection. 9 patients (5%) had sur-
gery supplemented by adjuvant or neoadjuvant therapy which involved radiotherapy, chemotherapy or both. 
In 77 cases (47%) chemotherapy was the only first line therapy. 9 patients (5%) had definitive radiotherapy of 
the primary tumor and 20 patients (12%) underwent combined radio-chemotherapy. Tyrosine kinase inhibi-
tors (TKIs), monoclonal antibodies or combinations of the former with chemotherapy were administered to 11 
patients (7%). Of note, many patients in that group were enrolled in clinical trials and no patient received immune 
checkpoint-inhibitor therapy. 6 (4%) patients received local therapy of a tumor site other than the primary tumor 
and moved on to best supportive care. 5 (3%) patients had no therapy other than best supportive care. In 7 cases 
(5%) data regarding therapy was missing. Medical records were also carefully reviewed for pneumonia or sepsis 
within 7 day prior or after the serum was analyzed for sTREM-1. If C-reactive protein was measured during this 
period, the values were also recorded. If a diagnosis of COPD was not known at first admission, pulmonary func-
tion test were used to newly diagnose COPD (post-bronchodilatator FEV1/VC < 0.7)48. Patient characteristics 
were summarized in Table 1.
Survival time was calculated from the date of histological or cytological diagnosis to death or last contact with 
the patient. If the patient was alive on the last contact, the survival time was regarded as censored. A progression 
of the cancer or recurrent disease assessed by CT scans was observed in 103 patients (63%, deaths not included). 
150 patients (92%) died during the follow up period (mean follow-up time: 24 months ± 35 months).
For the detection of soluble TREM-1 (sTREM-1) we used the assay published by Hasibeder et al.29: 50 μL 
of anti-TREM-1 (clone 6B1.1G12 mAb) were coated at 10 μg/mL in coating buffer (Na2HPO4 × 2H2O 0.1 M, 
pH = 9.3) at 4 °C over night and 37 °C for one hour respectively. Then plates were blocked with 200 μL blocking 
buffer (PBS 1%, BSA 1%) for 1.5 hours at RT. Afterwards the standard (recombinant human TREM-1 in 7.5% 
BSA-PBS) and the samples were added and the plates were incubated for 1.5 hours at RT. For analysis of sera 
samples, sera were diluted as indicated prior to addition to the plates (100 μL/well). After incubation for 1.5 hours 
plates were washed and the biotinylated detection polyclonal Ab anti-TREM-1 (R&D Systems Europe, Abingdon, 
UK) at 5 μg/mL was added for 1 hour at RT. Plates were then washed and streptavidine-HRP (R&D Systems, 
Europe, Abingdon, UK) was added for 20 min at RT. Plates were washed again, using the Tetramethylbenzidine 
Peroxidase Substrate System (KPL, Gaithersburg, Md, USA) and then the reaction was stopped by addition of 
H2SO4. All dilutions were carried out in blocking buffer. The absorbance was measured at 450 nm.
The results of serologic testing were compared with clinical parameters such as sex, age, CRP, LDH; CEA, 
Cyfra, NSE, TNM, histology, stage, presence of COPD, sepsis or pneumonia and response to therapy using either 
Fisher’s exact test or Mann-Whitney U-test. SPSS® 23 software (IBM) was used for the analysis. The median time 
between diagnosis and the blood sample for sTREM-1 was 6 days. Clinical data was not sufficient to rule out or to 
rule in sepsis or pneumonia at the time of sTREM-1 testing in 61 cases. CRP was reported in 75 cases. To examine 
the prognostic value of sTREM-1, we conducted several multivariable Cox proportional hazard regression models 
using a forward stepwise selection (inclusion criteria: p value of the Score test ≤ 0.05, exclusion criterion: p value 
of the likelihood ratio test ≥0.1). Model 0 included all patients (n = 164). We chose several subpopulations to 
answer the studies objectives. Subpopulation A comprised all patients with NSCLC (n = 137) and subpopulation 
B comprised all SCLC patients (n = 27). The patients with NSCLC stage I-IIIb are summarized in subpopulation 
C (n = 62). Patients with NSCLC stage IV form subpopulation D (n = 75). Recent data on the presence of sep-
sis, pneumonia or COPD at the time of diagnosis was available for 103 patients with SCLC and NSCLC. These 
patients were assigned to subpopulation E.
We considered: stage (1 vs. 2 vs. 3 vs. 4 or limited vs. extensive disease), age (as a continuous variable), sex 
(male vs. female), NSCLC sub-type (AC vs. other NSCLC, SCC vs. other NSCLC, LCC vs. other NSCLC44,45), and 
sTREM-1 (lower vs. higher than 163.1 pg/ml) as potential prognostic factors (reference category underlined). 
TNM-Staging43 was used in model 0 instead of stage grouping (Mountain46 or Veterans’ association47) to analyze 
both SCLC and NSCLC patients (n = 164). For the factors selected by the Cox regression models we compiled 
univariate Kaplan-Meier charts to visualize the results. We did not determine a global or local level of signifi-
cance, because we regarded all analyses as explorative. The datasets generated during and/or analyzed during the 
current study are available from the corresponding author on reasonable request.
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